AlphAIAlphAI — Financial news for AI agents
tokenpost.comOCT 252 min read$AGEN

Agenus Reports 72% Pathologic Complete Response in dMMR Colon Cancer Cohort

Agenus reported 72% pathologic complete response in 18 dMMR colon cancer patients treated with botensilimab and balstilimab in a Phase 2 study. 83% achieved major pathologic response. All patients were alive at 15-month median follow-up, with 16 showing no recurrence. The study was presented at the ESMO Congress.

Original reporting
tokenpost.com
Published Oct 25, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agenus Reports 72% Pathologic Complete Response in dMMR Colon Cancer Cohort — source image
Source · tokenpost.com
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

The data suggest a high efficacy signal for the botensilimab/balstilimab combo, which could accelerate development timelines and attract partnership interest.

02

Market read

First disclosure of strong Phase 2 results for a niche cancer indication; could drive short-term upside for Agenus and influence related biotech valuations.

03

What to watch

Potential safety signals and the investigational status of the drugs could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

Agenus presented the data at the ESMO Congress in a poster session, marking the first public release of the NEOASIS trial results for dMMR colon cancer.

Company-level read

Ticker impact

$AGENBullishHigh confidence
Context

Agenus disclosed Phase 2 data showing 72% pathologic complete response in dMMR colon cancer, a first public report of these results.

Expected impact

likely upward pressure as market prices in the strong response rates.

Evidence & confidence

First disclosure of high efficacy results in a niche oncology indication, a material catalyst for a biotech.

Market effects

Sector

May boost sentiment for other dMMR-focused biotech firms and immuno-oncology pipelines.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Highlights progress in checkpoint inhibitor combos, relevant to global oncology investors.

Counterpoint

What could challenge this read

Small cohort and lack of control arm could limit confidence; investors may wait for larger trials before buying.

Key entities

  • company
    Agenus Inc.

    Biopharma developing immuno-oncology therapies.

  • drug
    Botensilimab

    PD-1 inhibitor used in the trial.

  • drug
    Balstilimab

    CTLA-4 inhibitor used in the trial.

Read at source← All news

StoryAgenus reports 83% major pathologic response and 72% complete response in phase‑2 dMMR colon cancer trial

Also covered by

1 outlet

Related articles

OCT 27
$AGENMedAI 8/10

NEOASIS at ESMO 2026: Neoadjuvant Botensilimab Plus Balstilimab in dMMR Colorectal Cancer

Agenus presented Phase II NEOASIS study results at ESMO 2026, showing 83% pathological response rate in dMMR colorectal cancer patients treated with neoadjuvant botensilimab plus balstilimab. 72% achieved complete response. Safety profile included Grade 1-2 immune-related adverse events in 72% of patients, with one Grade 3 colitis case. The study met its primary endpoint, supporting further evaluation.

oncodaily.com3 min
OCT 25
$AGENMedAI 8/10

Agenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Agenus Inc. (AGEN) reported Phase 2 NEOASIS study results showing 83% of 18 patients with locally advanced dMMR colon cancer achieved a major pathologic response, with 72% having no cancer remaining at surgery after a 6-week course of botensilimab and balstilimab. Side effects were mostly mild. The company is exploring this approach in rectal cancer and MSS colon cancer.

finanznachrichten.de2 min
OCT 25
$AGENHighAI 8/10

After six weeks of treatment, 83% had little or no cancer remaining at surgery

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.

stocktitan.net2 min